Arvinas Inc (ARVN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Arvinas Inc stock (ARVN) is currently trading at $10.29. Arvinas Inc PS ratio (Price-to-Sales) is 2.68. Analyst consensus price target for ARVN is $14.88. WallStSmart rates ARVN as Sell.
- ARVN PE ratio analysis and historical PE chart
- ARVN PS ratio (Price-to-Sales) history and trend
- ARVN intrinsic value — DCF, Graham Number, EPV models
- ARVN stock price prediction 2025 2026 2027 2028 2029 2030
- ARVN fair value vs current price
- ARVN insider transactions and insider buying
- Is ARVN undervalued or overvalued?
- Arvinas Inc financial analysis — revenue, earnings, cash flow
- ARVN Piotroski F-Score and Altman Z-Score
- ARVN analyst price target and Smart Rating
Arvinas Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Arvinas Inc (ARVN) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Arvinas Inc (ARVN) Key Strengths (2)
86.69% of shares held by major funds and institutions
Trading at 1.61x book value, attractively priced
Supporting Valuation Data
Arvinas Inc (ARVN) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Revenue declining -84.00%, a shrinking business
Company is losing money with a negative profit margin
Small-cap company with higher risk but more growth potential
Revenue is fairly priced at 2.68x sales
Arvinas Inc (ARVN) Detailed Analysis Report
Overall Assessment
This company scores 29/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 9.0/10) while 6 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Price/Book. Valuation metrics including Price/Book (1.61) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (2.68) suggest expensive pricing. Growth concerns include Revenue Growth at -84.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -16.20%, Operating Margin at -755.00%, Profit Margin at -30.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -16.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -84.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ARVN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ARVN's Price-to-Sales ratio of 2.68x trades at a deep discount to its historical average of 68.99x (8th percentile). The current valuation is 99% below its historical high of 297.82x set in Jul 2021, and 52% above its historical low of 1.76x in May 2025. Over the past 12 months, the PS ratio has expanded from ~1.9x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Arvinas Inc (ARVN) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Arvinas Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 263M with 84% decline year-over-year. The company is currently unprofitable, posting a -30.8% profit margin.
Key Findings
Spending 23% of revenue (61M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 84% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -30.8% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Volatility is elevated with a beta of 1.94, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Arvinas Inc.
Bottom Line
Arvinas Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Arvinas Inc(ARVN)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Arvinas, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development, and commercialization of therapies to break down disease-causing proteins. The company is headquartered in New Haven, Connecticut.